Aura Biosciences Q1 2025 Update
Ticker: AURA · Form: 10-Q · Filed: May 15, 2025 · CIK: 1501796
| Field | Detail |
|---|---|
| Company | Aura Biosciences, INC. (AURA) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotechnology, financials, agreements
TL;DR
Aura Biosciences Q1 2025 10-Q filed. Financials and key agreements detailed.
AI Summary
Aura Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition, including its cash and cash equivalents and its net loss for the three months ended March 31, 2025. The filing also details various agreements, including a Collaboration Research and Development Agreement and an Exclusive License and Supply Agreement with LICOR Inc. The company's principal executive offices are located at 80 Guest Street, Boston, MA.
Why It Matters
This filing provides insight into Aura Biosciences' financial health and ongoing operational activities, which are crucial for investors and stakeholders to assess the company's progress and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Aura Biosciences faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 001-40971 — SEC File Number (Unique identifier for the company's SEC filings.)
Key Players & Entities
- Aura Biosciences, Inc. (company) — Filer
- March 31, 2025 (date) — Reporting period end date
- 80 Guest Street, Boston, MA (location) — Company address
- LICOR Inc. (company) — Party to agreements
- Dr. John Schiller (person) — Mentioned in relation to an agreement
FAQ
What was Aura Biosciences' net loss for the three months ended March 31, 2025?
The filing does not explicitly state the net loss amount for the three months ended March 31, 2025, but it indicates that financial results for this period are being reported.
What is the nature of the Exclusive License and Supply Agreement with LICOR Inc.?
The filing mentions an Exclusive License and Supply Agreement with LICOR Inc., but the specific terms and purpose are not detailed in the provided header information.
When was the Collaboration Research and Development Agreement entered into?
The filing references a Collaboration Research and Development Agreement, but the specific date of entry is not provided in the header.
What is the company's fiscal year end?
Aura Biosciences' fiscal year ends on December 31.
What is the company's SIC code and industry classification?
The company's SIC code is 2836, and it is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 by Dr. John Schiller regarding Aura Biosciences, Inc. (AURA).